MedTrace Logo

Hypertonic Saline for MAC

NCT04921943 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-08-15

No results posted yet for this study

Summary

The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.

Conditions

  • Nontuberculous Mycobacterial Lung Disease
  • Nontuberculous Mycobacterium Infection

Interventions

DRUG

Hypertonic saline

Nebulizing with 7% hypertonic saline twice daily for 12 weeks.

DRUG

Azithromycin

Standard of care

DRUG

Ethambutol

Standard of care

DRUG

Rifampin

Standard of care

Sponsors & Collaborators

  • NTM Info & Research, Inc.

    collaborator UNKNOWN

  • University Health Network, Toronto

    collaborator OTHER

  • New York University

    collaborator OTHER

  • Oregon Health and Science University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-18
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04921943 on ClinicalTrials.gov